HighMark Wealth Management’s Krystal Biotech KRYS Stock Holding History

HighMark Wealth Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-17,185	Closed	-$2.02M	–	576
2023 Q2	$2.02M	Hold	17,185	–	–	1.52%	10
2023 Q1	$1.38M	Hold	17,185	–	–	1.07%	12
2022 Q4	$1.36M	Hold	17,185	–	–	1.03%	16
2022 Q3	$1.2M	Hold	17,185	–	–	1.02%	12
2022 Q2	$1.13M	Hold	17,185	–	–	0.91%	16
2022 Q1	$1.14M	Hold	17,185	–	–	0.76%	15
2021 Q4	$1.2M	Sell	17,185 -191	-1%	-$11.1K	0.76%	16
2021 Q3	$907K	Buy	17,376 +99	+0.6%	+$5.86K	0.67%	19
2021 Q2	$1.18M	Buy	17,277 +85	+0.5%	+$5.93K	0.86%	14
2021 Q1	$1.32M	Sell	17,192 -394	-2%	-$28.6K	1.06%	12
2020 Q4	$1.05M	Sell	17,586 -1,308	-7%	-$65.3K	0.91%	13
2020 Q3	$813K	Buy	18,894 +1,525	+9%	+$66.2K	0.73%	16
2020 Q2	$719K	Buy	+17,369	New	+$836K	0.79%	14

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HighMark Wealth Management's KRYS Position: Q3 2023 in Review

HighMark Wealth Management sold out of Krystal Biotech (KRYS) in Q3 2023, closing a stake of 17,185 shares — an estimated $2.02M sold.

HighMark Wealth Management first reported a position in KRYS in Q2 2020 and held it in 13 quarters. The position peaked at $2.02M in Q2 2023. 188 funds tracked by Wall St. Rank hold KRYS as of Q3 2023.

HighMark Wealth Management reported no remaining Krystal Biotech position as of Q3 2023 after selling out during the quarter.
HighMark Wealth Management sold 17,185 Krystal Biotech shares in Q3 2023, an estimated $2.02M.
HighMark Wealth Management first reported a position in Krystal Biotech in Q2 2020 and held it in 13 quarters.
HighMark Wealth Management's Krystal Biotech position peaked at $2.02M in Q2 2023.
188 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2023.

Based on HighMark Wealth Management's 13F filing for Q3 2023, filed 18 Oct 2023.